Thousand Oaks Biologics and GeneQuantum Healthcare Signed A Strategic Partnership Agreement for ADC Drug Development

Thousand Oaks Biologics Inc. and GeneQuantum Healthcare Co., Ltd. are pleased to announce that they have formed a strategic partnership focusing on the CMC development of ADC products with a core conjugation technology for more stable drug candidates.

Scroll to Top